Dementia: Finance

(asked on 19th February 2024) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how the additional £95 million investment in dementia care has been allocated.


Answered by
Andrew Stephenson Portrait
Andrew Stephenson
This question was answered on 27th February 2024

The Dame Barbara Windsor Dementia Mission was launched in August 2022 with £95 million of Government funding. There is now more than £120 million of committed funding to the mission, which will be invested into three key pillars. The first pillar centres on biomarkers and experimental medicine, and will receive £50 million of the funding for the mission, with the intention of securing match funding from industry partners. As part of this pillar, Innovate UK launched a Small Business Research Initiative competition, with the aim of accelerating innovations in clinical biomarker tools and technologies for dementia, where organisations could apply for a share of £6 million of funding out of the allocated £50 million. These technologies will enable the discovery, validation, and implementation of a suite of decision-enabling biomarkers to help transform clinical trials and precision therapies. The competition closed on 4 September 2023, and the recipients awarded a portion of the £6 million will be announced soon.

The second pillar will focus on clinical trial infrastructure and innovation, with two recently announced initiatives to support its delivery. The first of these initiatives is the National Institute for Health and Care Research’s Dementia-Translational Research Collaboration Trials Network, with almost £50 million of funding over five years. This will expand the United Kingdom’s early phase clinical trial capabilities for dementia, speeding up the development of new treatments. The second initiative is the Clinical Trials Delivery Accelerator, focused on dementia, also named the Dementia Accelerator. This was announced in the Autumn Statement 2023, in response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK, with up to £20 million of additional funding.

The third pillar will be focused on end-to-end implementation, specifically on aligning translational research, clinical practice, and regulatory frameworks to prepare health-systems for new dementia medicines. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the Department, the devolved administrations, and the Dame Barbara Windsor Dementia Mission are already working closely together to plan for the implementation of new dementia medicines, should they gain approval in the UK.

Reticulating Splines